MAML2 and myoepithelial tumor: None of the additional AMEs subjected to RNA-sequencing harbored other fusion genes involving gene partners previously described in PAs,12 in myoepitheliomas of other anatomical sites (i.e., EWSR1 and FUS rearrangements),13,14 or in other tumors displaying myoepithelial differentiation (i.e., CRTC1-MAML2 fusion gene in mucoepidermoid carcinomas or MYB and MYBL1 rearrangements in adenoid cystic carcinoma).9,15 No additional likely pathogenic in-frame fusion gene was identified in the cases subjected to RNA-sequencing analysis (Supplementary Table 1).